Merck partners with Taiho, Otsuka in $2.5B bet on KRAS-targeting cancer drugs
The companies said Monday that they would partner to develop small-molecule oncology drugs against several targets, including KRAS mutations, long thought "undruggable." Amgen and Mirati have already presented clinical data from their KRAS programs.
